Source - SMW
Biotechnology company Destiny Pharma reported wider losses on higher costs in the first half of the year.

For the half-year ended 30 June 2020, pre-tax losses widened to £2.9m from £2.4m on-year. 
 
Administrative costs increased to £2.9m from £2.6m.
 
Looking ahead, the company said it was well funded to complete the Phase 2 clinical development of its lead drug asset, XF-73.  
 
'The company is currently designing the phase 3 clinical study that will hopefully follow,' it added. 


At 8:02am: (LON:DEST) Destiny Pharma Plc share price was 0p at 58p



Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.